Comments Plasma Proteome Offers Clues to Risk and Resilience in APOE4 Carriers 26 Jun 2026 ...
Kenneth Chen, M.D., Ph.D. Stanford University School of Medicine Contact Information Kenneth Chen, M.D., Ph.D. United States ...
Billions of years have passed since mitochondria left their freewheeling proteobacterial days behind them, but the nucleic acids within these endosymbiotic organelles still retain features of their ...
Proteomic panels come up short in the search for a plasma biomarker of Lewy bodies. AI may help.
Joseph A. Vita, MD Professor Boston University https://www.bumc.bu.edu/camed/profile/naomi-hamburg/ ...
This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...
Trappsol® Cyclo™ is a proprietary, intravenous formulation of 2-hydroxypropyl-β-cyclodextrin in development to treat diseases associated with impaired cholesterol metabolism, including Alzheimer's ...
Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...
It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite ...
Transferrin-receptor shuttles distribute antibody cargo throughout the parenchyma, steering clear of ARIA-provoking vascular amyloid. Trontinemab is enrolling Phase 3 for early AD, announces plans for ...
First trial of concurrent amyloid and tau immunotherapies in sporadic Alzheimer’s is underway. Safety data are a go for subcutaneous remternetug. Plaque removal correlates with cognitive benefit in ...
CAR-T cell therapy has practically become a household name, given its success in taking down blood cancers. The chimeric antigen receptors used in this type of cell therapy are designed to sic killer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results